Perianal manifestations of Crohn's disease (CD) are common and, of them, fi stulas are the most common. Perianal fi stulas can be extremely debilitating for patients and are oft en very challenging for clinicians to treat. CD perianal fi stulas usually require multidisciplinary and multimodality treatment, including both medical and surgical approaches. Th e majority of patients require multiple surgical interventions. CD patients with perianal fi stulas have a high rate of primary nonhealing, surgical morbidity, and high recurrence rates. Th is has led to constant eff orts to improve surgical management of this disease process.
Introduction
Perianal manifestations aff ect anywhere from 20-54% of patients with Crohn's disease (CD) and this proportion may be even higher in referral-based practice populations [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Th ough perianal CD can be present ranging anywhere from over a decade prior to diagnosis of CD to over 30 years aft er the initial diagnosis of CD, it is usually diagnosed concurrently or within a few years of diagnosis [2, 6, [10] [11] [12] [13] [14] .
Perianal CD is a predictor of overall severity of CD and, with its presence, there is an increased risk of postoperative recurrence, an increased risk of requiring surgical intervention, and a shorter time between recurrences [3, [15] [16] [17] . Th e more distal intestinal luminal CD lesions are at higher risk of developing associated perianal disease [6] . Approximately 20% of patients with perianal CD have other sites of disease in the small bowel or ileocolic area, while the remainder have manifestations in the colon and rectum [3, 6] . In a small percentage of patients, CD symptoms manifest only in the anorectum [18] . Perianal lesions usually develop and/or fl are temporally with intestinal recurrences of the disease [10, 19] .
Perianal CD can be extremely debilitating for patients, and is oft en very challenging for clinicians to treat. Substantial multidisciplinary medical and surgical care is required [2] .
Th e most common manifestation of perianal CD is perirectal/ perianal fi stula (50-87% of all perianal lesions); others include fi ssure, anal canal stricture, rectovaginal fi stula, and abscess [2, 3, 13] . Over half of CD patients with perianal disease have more than one perianal lesion [3, 12, 20, 21] .
Perianal CD fi stulas can be classifi ed as simple or complex. A simple fi stula is a low lesion with a single external opening, whereas a complex fi stula is one that recurs, or one with multiple tracts, high above the sphincter complex [8, 12] . Patients with CD are at a higher risk of developing complex fi stulizing disease, which is inherently more diffi cult to treat [12] . Multiple surgical treatments are usually required to achieve healing, with a median of six procedures for complex fi stulas and median of three for simple fi stulas. Furthermore, up to 38% of complex perianal fi stulas will require major surgical intervention, including defunctioning stoma or proctectomy [12, [22] [23] [24] . Th e ultimate goals of treatment are to defi ne the anatomy, drain sepsis, and gain permanent closure of the fi stulous tracts [25, 26] . To achieve healing, complex fi stulas usually require combined surgical and medical management [8] .
Whether the fi stula is simple or complex, up to 90% of patients with perianal CD will require operative treatment, and many will require more than one operative intervention [11, 27] . When operations for perianal CD are performed, it is oft en diffi cult to achieve complete healing. In addition, there are increased risks of devastating complications, including septic complications, anal stenosis, and incontinence [9, 28] .
Patients with perianal CD are at a high risk of incontinence, due to the complex nature of their disease, frequent diarrhea, and need for multiple operative interventions that put the sphincter complex at risk. Patients with perianal CD are also at risk for prolonged fi stula healing and frequent recurrences. It is not uncommon for a CD fi stula to take many months, and even years to heal. More than 20% of patients do not achieve complete fi stula healing in most studies [12, 21] . Similarly, fi stula recurrences are common, occurring on average in 20-35% of cases, even with intensive combination therapy [12, 21] . Many recurrences occur years aft er initial closure, sometimes up to fi ve years later, yet many studies are not able to provide longterm follow up [6, 11, 12, 21, 29, 30] .
Interestingly, in some cases when intestinal CD lesions are operatively removed, the associated perianal disease will resolve. In one series of 43 patients, there was a 47% spontaneous healing rate of the perianal disease aft er resection of intestinal lesion; however, 35% of these recurred within 2.5 years [6] . Th is stresses the importance of delineating any other active intestinal disease that may need treatment prior to operative treatment of perianal disease [31] . It is also crucial to assess anatomy, sphincter function, continence, patient nutritional status, and quality of life [31] .
Combination therapy
A combined medical and surgical approach to treatment is integral to the care of CD perianal fi stulas [8] . Medical treatment includes antibiotics, immunomodulators, and biologic medications [26, [32] [33] [34] [35] [36] . Aft er being approved for use in CD in 1998, and with further reinforcement of their effi cacy in perianal CD fi stulas in 1999, biologic therapies are being widely used by gastroenterologists in all practice settings [37] [38] [39] [40] . Th e most commonly used biologic therapy is infl iximab (IFX), an anti-tumor necrosis factor (TNF)-α drug [37] . Adalimumab is another anti-TNF-α medication indicated in cases refractory or intolerant to IFX [26, 41] .
According to the National Institute for Health and Care Excellence guidelines, biologics should be reserved for CD that has failed conventional therapy or in the presence of severe, active fi stulizing disease [42, 43] . Th is is echoed by the European evidence-based consensus on CD [36] . IFX treatment of perianal CD aft er local surgical drainage resulted in an overall 55% closure. Duration of fi stula closure is limited, however, with a median of three months of continued fi stula closure [39] . Recurrence rates were 17% at one year and 40% at fi ve years [39, 44] . Th ere seems to be some benefi t to continuation with IFX maintenance therapy, which resulted in a 36% response rate at 54 weeks, compared to 19% in the placebo group [45] .
In the adolescent population, response to IFX may be slightly improved, as there was a 70% complete response, with a 23% recurrence rate aft er seton drainage and IFX. Th ese patients, however, had their setons left in much longer than their adult counterparts. In addition, many of this cohort were switched to adalimumab treatment [46] .
Despite major advances in medical treatment, biologic medications and immunomodulators do not seem to signifi cantly change the biology or long-term prognosis of patients with perianal CD, and surgical treatment remains a necessity [31, 34, 38, 39, 47] . Th ere is a signifi cant nonresponse rate, 20-35% in most series. Even with closure of perianal fi stula aft er IFX, many patients require further surgical intervention for recurrence, development of anal stenosis, or abscess formation.
Anal stenosis is postulated to be due to scarring from rapid healing while on IFX [1, 38] . In a series of nine patients with perianal fi stulizing CD, Poritz et al demonstrated an initial 44% complete response rate to perianal fi stulas; however, another 44% went on to require surgical intervention [38] .
Prior to treatment with biologic medications, most patients have a surgical exam under anesthesia (EUA) with drainage of local infection and seton placement to keep fi stulous tracts open. Th ere are some, however, who have questioned whether this is necessary [1, 47] . In a study by Regueiro et al, patients who had an EUA with seton placement prior to biologic medical therapy had better initial response, lower recurrence rate, and longer time to recurrence, when compared to those treated with biologic therapy alone [47] . Other authors have demonstrated similar results with other pre-IFX operative treatments, including fi stulotomy, fi brin glue administration, rectal advancement fl ap procedure, or defunctioning stoma [1, 20] .
IFX as a treatment is not without risk. Multiple serious adverse reactions have been reported including serum sickness, severe septic infections, drug-induced lupus, and malignancies [38, 40, 48] . It remains unclear how long IFX should be continued in patients as maintenance therapy [1, 20, 45] . Relapses are common aft er discontinuation of therapy [33, 49] , with only 34% of patients maintaining perianal remission at one year aft er stopping IFX treatment [49] . It is also important to weigh the cost of biologic therapies for the treatment of perianal CD, as they are the largest healthcare expense involved with this disease process [50] .
EUA and imaging
EUA is a diagnostic procedure, but it is oft en a therapeutic and preventative procedure as well [32, 33] . Th e goals of treatment are to defi ne the anatomy, drain perianal sepsis, and attempt to prevent septic recurrence, while maintaining continence and quality of life [33] . When performing an EUA, it is prudent to include the scrotum or vagina in fi eld, as it is possible for fi stulizing disease to involve these areas. Gentle probing and use of methylene blue or hydrogen peroxide to defi ne fi stulous tracts is commonly successful [33] .
Recently, there has been more frequent use of magnetic resonance imaging (MRI) to help characterize fi stulizing disease [51] . MRI is oft en performed prior to EUA to help delineate anatomy and identify any additional occult abscesses or fi stulous tracts prior to operative exploration [33] . Endoscopic ultrasound (EUS) and transperineal ultrasound have also similarly been used and have shown to be successful with experienced ultrasonographers [17, 32, 52] . Fistulography as a diagnostic modality is no longer used in this disease process [32, 36] .
MRI, EUS and EUA all have similar accuracy in identifying fi stula tracts. When two of the three tests are combined, accuracy is 100% [53] . Th e European Crohn's and Colitis Organisation (ECCO) consensus guidelines currently advise obtaining an MRI initially in complex fi stulizing CD [32, 36] .
In addition, proctoscopy is recommended to determine if concomitant active rectal disease is present for diagnostic, prognostic, and therapeutic planning [32, 36] .
Incision and drainage of abscesses
Th e most common indication for operative intervention with perianal CD is septic complications, which include abscesses or undrained fi stulas [31] . All clinically symptomatic abscesses require incision and drainage [8, 27, 36] . Th is is usually required urgently or emergently to control sepsis [7] . Small (<1 cm), clinically occult abscesses that are demonstrated on imaging can generally be treated with medical therapy alone [51] .
It is important to recognize the relationship between an abscess and, most likely, an associated fi stulous tract in CD patients. In one small series by Williamson et al, all patients who underwent drainage of abscesses only failed treatment [21] . Confl icting results were found by Michelassi et al, who demonstrated complete healing in 68%, with only 32% going on to develop fi stulizing disease [27] . It is important to note that perianal abscesses have been reported to represent a complication of IFX treatment, possibly due to cutaneous end closure prior to internal opening closure [38] . In a population-based study, Jones et al found that since the approval of biologics for use in CD, the incidence of anal fi stula repair has remained stable, but perianal abscess incision and drainage has increased threefold [54] .
Seton placement
A seton is a silastic loop or suture that is placed in a fi stulous tract and left in place. Setons are used to keep fi stulous tracts open, allowing them to drain in order to prevent reaccumulation of undrained sepsis. As long as non-cutting setons are used, the risk of sphincter damage or compromising continence are low. Also, setons can be left in place long-term while medical treatments are used. Unfortunately, when setons are removed, there is a high recurrence rate of recurrent local sepsis, up to 70% [18, 55] . Removing setons may have initial short-term healing success, but if followed longer, most patients will have recurrence, especially in the absence of additional treatment [56] . For this reason, some advocate permanent seton placement in this patient population [8, 12, 18, 55, 57] .
If removal of a seton is planned, optimal timing of when to remove it is unclear. If setons are removed too early, there is a high risk of development of recurrent perianal abscess. If one is not removed quickly enough, however, the presence of a foreign body will prevent complete fi stula healing [38, 46] . Furthermore, timing of seton placement and removal in coordination with IFX use is controversial [32, 36, 38] .
Seton drainage is oft en used as a temporary control of fi stula drainage until the patient's condition is appropriate to undergo a defi nitive fi stula closure [24] .
Fistulotomy
For low-lying, asymptomatic, simple fi stulae, no treatment is necessary, as the risks of a procedure outweigh the benefi ts [8] . However, if a simple fi stula is symptomatic, seton placement or fi stulotomy are usually appropriate [5, 12, 18, 19, 26, 27, 31, 32, 36, 58, 59] .
As CD patients have a high risk of recurrence, usually undergo multiple operative procedures and are at risk of incontinence, many clinicians are hesitant to perform fi stulotomies in this patient population. However, fi stulotomy procedures with low, simple fi stulas have been demonstrated to have an excellent response rate with minimal complications [5, 57] . It is important to note that this patient population may have delayed healing and increased risk of recurrence compared to patients without CD. It is not uncommon to achieve complete healing six months aft er this procedure [5, 57] .
Fistulotomy is generally contraindicated in patients with complex fi stulas, as they have an unacceptably high risk for incontinence, non-healing of wounds, and need for proctectomy [10, 32, 60] . Similarly, when macroscopic rectal involvement is present, patients have a decreased rate of healing [8, 10] . Caution should also be used in patients who have diarrhea, women with anterior fi stulas, and patients with short anal canals [8] .
Incontinence rates aft er fi stulotomy have been variably reported in the literature anywhere from 0-50% [5, 9, 18, 35, 57, 61] . Some authors advocate partial fi stulotomy with seton placement as an alternative, as this procedure minimizes sphincter compromise [21, 57] . Others advocate the use of laser ablation to unroof fi stula tracts, with similar results to fi stulotomy [62, 63] .
Fecal diversion
Fecal diversion consists of stoma formation to divert the fecal stream away from wounds to allow healing. Th is approach is oft en used in anticipation of restoration of bowel continuity once complete healing is achieved. In a series of 86 patients with perianal CD, 62% required fecal diversion at some point during care, and approximately 50% of patients required permanent fecal diversion [3] . In another study of 31 patients who underwent fecal diversion and drainage of local sepsis for their perianal disease, 81% went into early remission, although 68% of these relapsed at a median of 23 months aft er diversion. A total of 25% of patients had long-term remission, but only 10% were able to restore intestinal continuity [64] . Similarly, dismal results were found in other smaller studies [65, 66] . Th is refl ects the fact that fecal diversion does not alter the course of disease. Disease oft en recurs aft er closure of ostomy, and disease recurrence has also been reported while patients are still diverted. Restoration of intestinal continuity is uncommon [67, 68] . Predictors of the need for permanent fecal diversion are presence of colonic disease, anal canal stricture and increased number of surgical interventions [3] .
In contrast, in a series of 14 patients who had fecal diversion in addition to local therapy and medical treatment, only two (14%) developed symptomatic recurrence of their perianal disease, with a median 22-month follow up [59] . Th is suggests that fecal diversion possibly should be used only as an adjunct to other treatments, and not as a defi nitive treatment in itself. Th is is supported by another series of 97 patients with perianal CD. In this series, 53% of patients required temporary fecal diversion, but 47% of these were successfully closed aft er the fi stula was treated, using a rectal advancement fl ap [24] .
Fibrin glue
Fibrin glue is applied to the fi stulous tract in attempts to promote healing and closure. Th e advantage of this therapy is the overall very low complication rate and the almost zero risk of incontinence. In a randomized multicenter trial of highly selected CD patients, fi brin glue was associated with a 38% success of closure rate, as opposed to 16% in the observationalone group at eight-week follow up [69] . Th e benefi t in this trial was more pronounced in the patients with simple fi stulas, as compared to complex ones. Additionally, 15% of the successfully closed fi stulas recurred at 16 weeks. Very limited or no response to fi brin glue has also been observed by others [70, 71] . In a French trial of 14 patients with CD, there was clinical resolution of 57% of fi stulas aft er 23 months of follow up. When evaluated endoscopically, however, only 14% had endoscopic resolution, suggesting that these tracts may be quiescent, but at risk to recur in the future [22, [72] [73] [74] [75] .
A group in Spain combined adipose-derived stem cells with fi brin glue injection and found improved results compared to fi brin glue alone; 71% healing versus 14% in the glue alone cohort. However, recurrence increased by 17.6% at one year of follow up, and with further follow up at three years, only 28% were free of recurrence [76, 77] .
A summary of outcomes in the literature of fi brin glue injection are listed in Table 1 . Despite little success with fi brin glue in healing CD perianal fi stulas, some advocate its use as an option due to very few complications, including absence of incontinence. Th e risks and benefi ts should be weighed and individualized, as the glue is usually applied under anesthetic and does incur cost.
Fistula plug
Th e anal fi stula plug is a porcine intestinal submucosal xenograft that is bioabsorbable. It is inserted into the perianal fi stulous tract, with the objective of promoting fi stulous tract closure while preserving continence [78] [79] [80] . Th ere was an 80% closure rate of perianal fi stulas with a median of ten months follow up in a series of 20 CD patients by O'Connor et al. Presence of multiple fi stulous tracts was a risk factor for procedure failure. In this series, use of anti-TNF-α therapy did not correlate with outcomes [79] . A subsequent systematic review of anal fi stula plug use in 42 patients with perianal CD demonstrated a 55% success rate of the procedure.
Th is was similar to the success rate in the non-CD patient population [80] . Th ere were no reports of incontinence; however, abscess formation has been reported. A summary of outcomes in the literature of fi stula plug are listed in Table 1 . It remains unclear how to select CD patients for this procedure as long-term follow-up data is limited; however, McGee et al demonstrated that longer fi stula tract length was associated with improved fi stula closure in non-CD patients [81] .
Endorectal mucosal advancement fl ap
Endorectal mucosal advancement fl ap is a procedure that uses endogenous tissue to close the internal fi stula opening. Th e use of this procedure is performed to avoid dividing sphincter muscle, but incontinence has been described as a complication to the procedure [59, 74] . Th ere is an option of performing a second fl ap procedure if an initial operation fails; however, multiple fl ap repairs have an increased risk of incontinence [27, 30, 82] . Proctitis is a contraindication to the procedure due to poor healing. In addition, repair has been shown to be less successful if there is active CD elsewhere in the GI tract that is not well controlled. During the initial healing period in high-risk patients, it is common for surgeons to use a protective stoma [83] .
Prior to receiving an advancement fl ap, most patients have undergone a period of infection control with a draining seton, with or without a diverting stoma [84] . Once the acute infl ammation and infection have subsided, patients undergo the operation. Success rates have been variable and have been reported to be anywhere from 25-64% [18, 21, 29, 30, 59, 82, 83] . In a systematic review, however, the overall success of endorectal advancement fl aps in CD was found to be 64%, compared to 81% in non-CD counterparts. Th e incontinence rate of the procedure was slightly lower in patients with CD than in those non-CD counterparts, at 9.4% and 13.2% respectively [85] .
Although active proctitis is a contraindication to the procedure, van der Hagen et al demonstrated good results with preoperative IFX treatment for patients with active proctitis in a pilot study. If the proctitis resolved, the patient was indicated for fl ap procedure. In this small patient cohort with limited follow up, there was only a 10% recurrence rate and a 10% rate of incontinence in the pre-treated patients, compared to 29% recurrence and incontinence rates in the group that did not have IFX prior to fl ap procedure [86] . Th is study suggests that with modern biologic therapy, we may be able to expand indications for this potentially defi nitive operation.
If anal stenosis is present, precluding attempted rectal advancement fl ap, rectal sleeve advancement has been reported to be successful in a very limited number of cases [87] .
Ligation of the intersphincteric tract (LIFT) procedure
A fairly new technique that has also shown some early success in healing complex perianal fi stulas while preserving continence is the LIFT procedure [88] . In a series of 15 CD patients, Gingold et al demonstrated a 67% wound healing rate at one-year follow up without any fecal incontinence. None of the fi ve midline fi stulas in this series were successfuly healed with this approach, but there was a 90% success rate with lateral fi stulas. Th e procedure was also more eff ective in patients with longer tracts (average length of tracts that resulted in successful procedure was 34 mm as opposed to 20 mm in failed procedures). Interestingly, even aft er successful LIFT procedure, there was a 20% incidence of new fi stula formation [23] . Additional studies of this procedure are needed in the CD population to verify it as a viable and safe option in this patient population.
Other treatments Hyperbaric oxygen
When combined with surgical and medical treatment, hyperbaric oxygen treatment has been used with some success in a few case reports [85] [86] [87] .
Topical tacrolimus
While there seems to be a role for topical tacrolimus in healing refractory perianal CD ulceration, this treatment does not seem to be successful, and may actually be harmful in the setting of perianal fi stulizing CD [89] [90] [91] . In a placebocontrolled trial by Hart et al, topical tacrolimus did not result in any improvement in fi stulizing disease in the six patients in the treatment arm. In addition, two patients in the treatment arm developed abscesses, thought to be a complication of the drug in this setting [90] . A summary of outcomes in the literature of topical tacrolimus are listed in Table 2 .
Local biologic injection
Injection of biologic medications locally surrounding the fi stulous tract is a procedure usually performed in the operating room under general or spinal anesthesia [92] [93] [94] . In a study of 15 patients with refractory perianal fi stulizing disease treated with local injection of IFX, 67% had closure of their fi stulas at a mean of 18-month followup. Twenty percent of these patients, however, had adverse events, including incontinence and anal stricture [93] .
Th ere have been improved results reported with local injection of adalimumab [92, 94] . In a series of 9 patients with CD perianal fi stula, Tonelli et al demonstrated improvement in 3/9, or complete cessation of drainage in 6/9 patients with a 17-month median follow up; and there were no adverse events in this group [94] . A summary of outcomes in the literature of local biologic injection are listed in Table 2 . Further clinical trials are necessary, but this remains a promising treatment option for patients who are otherwise refractory to, or who have contraindications to infusional biologic therapy.
Proctectomy
Proctectomy is usually used as the last resort option in an attempt to heal perianal fi stulizing CD. In a series by Bell et al, the median number of treatments attempted for healing prior to proctectomy was 12, with a median time from presentation with perianal disease to proctectomy of 6.3 years [12] . Proctectomy rate has been variably reported anywhere from 12-38% of patients with perianal fi stulizing CD [5, 7, 12, 18, 21, 27, 55] . Multiple operations and multiple complications increase the risk of proctectomy [27, 31] . In addition, Crohn's colitis with rectal sparing, but presence of perianal fi stulizing disease, resulted in a 46% proctectomy rate. Colonic disease with rectal involvement required proctectomy in 89% of patients with perianal fi stulas [6] .
When a proctectomy is required for disease control in this patient population, there is oft en diffi cult healing of the perineal wound [9, 31] . In one series, only 23% healed at six months, as opposed to healing in 50% of CD patients without perianal disease [10] . Myocutaneous fl ap coverage aft er proctectomy for perianal CD has demonstrated good results in improved healing. It is advisable to perform the fl ap at the initial operation for proctectomy for wound coverage. Th e literature suggests better outcomes with rectus abdominus fl ap than with gracilis fl ap [95, 96] . 
Predictors of recurrence
Th e presence of active proctitis increases not only the risk of having perianal fi stulizing disease but also portends increased risk of refractory, recurrent disease that will require proctectomy [5, 7, 12, 27, 31, 66] . Hurst et al demonstrated a 67% proctectomy rate in patients with perianal fi stulizing disease and gross evidence of proctitis versus 11% in those with fi stulizing disease but without macroscopic rectal involvement [7] .
Crohn's colitis is also a very strong predictor of treatment failure with a recurrence rate of 84-100% [6, 10, [57] [58] [59] . Uzzan et al attempted treatment for severe Crohn's colitis with associated perianal disease with ileal diversion and biologic medications in a series of three patients. All three patients failed therapy and ultimately required permanent stoma [97] .
In addition to proctitis and Crohn's colitis, complex fi stulas and absence of fecal diversion, are also risk factors for symptomatic recurrence [59] . In all CD lesions, but especially a refractory lesion, one must always have a high index of suspicion for development of carcinoma in fi stula tracts. Biopsy or curettage with pathologic evaluation of fi stulous tracts should be performed if there is any suspicion of malignancy [8, 98, 99] .
Hidradenitis suppurativa (HS)
It is important to note the association and diagnostic diffi culty of perianal HS and perianal CD [100] . HS is a chronic apocrine sweat gland disorder that can cause abscesses, sinuses, and fi stulas in the perineum and other areas where apocrine glands are present such as the axillae [100, 101] . Th e association of this pathology with CD is largely unknown but reported retrospectively anywhere from 0.6-38% [100, 102, 103] . Th e diagnostic distinction can be quite diffi cult as areas of HS can have associated granulomas, a histologic feature of CD [100] . In Figure 1 Proposed algorithm for the treatment of perianal fi stulas due to Crohn's disease addition, HS responds to treatment with biologic medications, further complicating the distinction [103] . Diagnostic vigilance is important as aggressive surgical excision has the most favorable operative outcome, generally the opposite approach than that for perianal CD lesions [100, 104] . Wide excision of HS lesions is usually feasible even within the CD population as HS generally does not involve or extend to the sphincter complexes [104] . Of importance, perianal HS has also been associated with development of squamous cell carcinoma aft er longstanding lesions. Early diagnosis with aggressive treatment of HS lesions may prevent malignant transformation [105, 106] .
Concluding remarks
Even with modern medical and surgical advancements for treatment of perianal CD, it remains challenging to treat. Most of the literature to guide our practice is based on small case series, oft en with limited follow up. With most of the existing case reports and series it is hard to draw conclusions, especially considering the variability of disease presentation. Th ere is still no one defi nitive or long-term eff ective treatment for all perianal CD. Recurrences are high and surgical treatments must be individualized in order to minimize risks. A proposed algorithm is shown in Fig. 1 . It is imperative that perianal CD fi stulizing disease is approached with a multidisciplinary team comprising surgeons, gastroenterologists, radiologists and pathologists.
